The average price target for this small-cap drugmaker's stock, $19.06 (per ... Sign Up For Free » Terns Pharmaceuticals focuses on developing weight loss and oncology medicines.

The company, best known for its work in immunology, recently made a move to enter the weight loss space. Does that make AbbVie stock a buy today? Developing therapies from scratch is risky and ...

Finance), implies that the stock could skyrocket by about 462% from its current levels. Does that make it a buy? Terns Pharmaceuticals focuses on developing weight loss and oncology medicines.

Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss ... cap drugmaker's stock, $19.06 ...